Monoamine oxidase-A (MAO-A) low-expression variants and increased risk of Plasmodium vivax malaria relapses.
Maria Carolina Silva De Barros PuçaDanielle Fonseca RodriguesYanka Evellyn Alves Rodrigues SalazarJaime LouzadaCor Jesus Fernandes FontesAndré DaherDhélio Batista PereiraJosé Luiz Fernandes VieiraLuzia Helena CarvalhoCristiana Ferreira Alves de BritoJosé Pedro GilTais Nobrega de SousaPublished in: The Journal of antimicrobial chemotherapy (2024)
We found evidence that the low-expression MAO-A variants can potentiate the negative impact of impaired CYP2D6 activity, resulting in lower levels of carboxyprimaquine metabolite and multiple relapses. The findings support the hypothesis that carboxyprimaquine may be further metabolized through CYP-mediated pathways generating bioactive metabolites that act against the parasite.